SiteOne Therapeutics is dedicated to developing novel pain therapeutics to safely, effectively and efficiently treat acute and chronic pain without the limitations of existing drugs, such as opioids. Given the critical role that NaV1.7 plays in the generation and conduction of pain signals, combined with the urgent need for new, non-opioid pain therapies, SiteOne is focused on advancing its lead products to serve patients that suffer from moderate to severe pain.
SiteOne's unique approach has enabled the discovery of highly-selective small molecule inhibitors of an important target in pain signaling, the Nav 1.7 sodium channel.
News & Updates
Read more about our current rounds of funding, updates on our research, & stories from the biotech industry.
Pain & The Opioid Crisis
Learn how SiteOne is developing a completely new class of non-opioid, non-NSAID pain treatments which selectively interrupt pain signals before they engage the central nervous system.